Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MTEM save search
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 13:30) - biospace.com/
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402 association tumors cancer research for meeting molecular study
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402 association tumors cancer research for molecular study
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Published: 2024-03-29 (Crawled : 12:30) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
| Email alert
Add to watchlist
business update financial results molecular
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 18.3%
H: 0.0%
C: -19.42%
million offering agreement molecular
Molecular Templates, Inc. Provides Interim Update
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 11.96%
H: 0.0%
C: -6.55%
update molecular
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-08 (Crawled : 23:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: -1.13%
conference life sciences molecular
Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
ACLX | $52.795 -3.02% -3.12% 300K
|
|
| O: 0.2%
H: 5.99%
C: 5.65%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -2.94%
H: 3.03%
C: 3.03%
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 0.43%
H: 0.27%
C: -0.6%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.66%
H: 0.64%
C: -1.11%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: 1.1%
H: 0.27%
C: -1.64%
companies growth market
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -3.75%
H: 5.16%
C: 1.3%
business update financial results molecular
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 8.15%
H: 1.13%
C: -5.65%
mt-8421 tumors trial molecular
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
VTVT | $25.39 1.66% 1.63% 4.2K
|
Health Technology
|
| O: -0.02%
H: 2.44%
C: -2.37%
OMER | $3.04 -1.62% -1.64% 250K
|
Health Technology
|
| O: 1.77%
H: 6.96%
C: 6.09%
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 3.5%
H: 0.0%
C: -5.12%
medical therapeutics
Molecular Templates to Participate in Upcoming Investor Conferences
Published: 2023-11-01 (Crawled : 20:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 3.5%
H: 0.0%
C: -5.12%
molecular
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
Published: 2023-09-28 (Crawled : 20:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 2.11%
H: 4.78%
C: 0.64%
medical molecular
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
Published: 2023-08-28 (Crawled : 12:00) - globenewswire.com
ELTX | $9.25 0.33% 0.32% 25K
|
|
| O: -0.62%
H: 0.1%
C: -1.88%
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -2.55%
therapeutics
Molecular Templates Announces 1-for-15 Reverse Stock Split
Published: 2023-08-11 (Crawled : 15:20) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -1.46%
H: 7.12%
C: 3.22%
molecular
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
Published: 2023-08-10 (Crawled : 12:20) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: -0.17%
H: 0.8%
C: -1.65%
business update financial results molecular
Molecular Templates Announces Executive Leadership Changes
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 1432.55%
H: 2.94%
C: -2.03%
molecular
Molecular Templates Announces Up to $40 Million Private Placement Offering
Published: 2023-07-13 (Crawled : 12:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 6.6%
H: 1.8%
C: 1.8%
offering molecular
Molecular Templates Announces Debt Payoff and Restructuring
Published: 2023-06-17 (Crawled : 04:20) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
| Email alert
Add to watchlist
molecular
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
Published: 2023-06-01 (Crawled : 12:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
|
| O: 2.13%
H: 1.88%
C: -1.6%
mt-0169 fda removal trial molecular
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-05-26 (Crawled : 21:00) - globenewswire.com
MTEM | $1.55 3.54% 15K
|
Health Technology
| Email alert
Add to watchlist
mt-6402 meeting molecular study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.